---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010303"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T12:36:47.259127+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kodiak Sciences Q4 net loss $70.4M ($1.35/sh); cash $478.9M; tarcocimab data Q3 2023

## Summary
- Cash, equivalents and marketable securities totaled $478.9M at Dec 31, 2022.
- Q4 2022 net loss $70.4M ($1.35/sh) vs Q4 2021 net loss $93.2M ($1.79/sh).
- R&D expenses $56.0M in Q4 2022, down from $75.6M; G&A $18.1M vs $17.5M.
- Topline data from 4 Phase 3 tarcocimab studies (DME, NPDR, wAMD) expected Q3 2023.
- KSI-501 Phase 1 in DME screening patients; commercial cGMP manufacturing started at Ursus.

## SEC filing metadata
- accession: 0000950170-23-010303
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000095017023010303/0000950170-23-010303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000095017023010303/kod-20230328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010303
- JSON: https://secwatch.observer/filing/0000950170-23-010303.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010303.txt

## Key facts
- Earnings Releases
  Kodiak Sciences Inc. reported financial results for the fourth quarter ended December 31, 2022.
  - Period: the fourth quarter ended December 31, 2022
  - Result: reported results
  source text: Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468748/000095017023010303/0000950170-23-010303-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.